(Q35127256)

6 August 2017

1 reference

title

Minireview: primary aldosteronism--changing concepts in diagnosis and treatment (English)

1 reference

https://api.crossref.org/works/10.1210/EN.2003-0279

6 August 2017

Minireview: Primary Aldosteronism—Changing Concepts in Diagnosis and Treatment (English)

1 reference

2 January 2024

1 reference

https://api.crossref.org/works/10.1210/EN.2003-0279

2 January 2024

author name string

William F. Young

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12746276

reference URL

2 January 2024

language of work or name

English

0 references

publication date

1 June 2003

1 reference

full work available at URL

6 August 2017

published in

Endocrinology

1 reference

6 August 2017

volume

144

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

2208-2213

1 reference

A chimaeric llβ-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension

6 August 2017

cites work

https://api.crossref.org/works/10.1210/EN.2003-0279

2

1 reference

New genetic insights in familial hyperaldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

3

1 reference

Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

6

1 reference

Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

8

1 reference

The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

9

1 reference

High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

10

1 reference

Primary aldosteronism: management issues

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

11

1 reference

Hyperaldosteronism among black and white subjects with resistant hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

12

1 reference

Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

13

1 reference

A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

14

1 reference

Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

16

1 reference

Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

17

1 reference

The diagnosis of primary aldosteronism and separation of two major subtypes

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

18

1 reference

Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

19

1 reference

Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

20

1 reference

High incidence of primary aldosteronism in 199 patients referred with hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

21

1 reference

High prevalence of primary aldosteronism in the Tayside hypertension clinic population.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

24

1 reference

Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism?

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

28

1 reference

Potentially high prevalence of primary aldosteronism in a primary-care population

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

30

1 reference

Screening for primary aldosteronism with a logistic multivariate discriminant analysis

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

32

1 reference

Primary aldosteronism: are we diagnosing and operating on too few patients?

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

34

1 reference

Diagnostic value of the post-captopril test in primary aldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

36

1 reference

Functional tests for primary aldosteronism: value of captopril suppression

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

37

1 reference

Cautions over the current epidemic of primary aldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

38

1 reference

Primary aldosteronism, a common entity? the myth persists

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

39

1 reference

Primary aldosteronism: factors associated with normalization of blood pressure after surgery.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

40

1 reference

Incidentally discovered adrenal masses

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

42

1 reference

Diagnosis and treatment of primary hyperaldosteronism.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

43

1 reference

Primary aldosteronism: adrenal venous sampling

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

44

1 reference

Hyperaldosteronism: sampling the adrenal veins

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

47

1 reference

Aldosterone induces a vascular inflammatory phenotype in the rat heart

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

48

1 reference

The pathophysiology of aldosterone in the cardiovascular system

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

49

1 reference

Aldosterone as a mediator in cardiovascular injury

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

50

1 reference

Remodeling of the rat right and left ventricles in experimental hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

52

1 reference

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

53

1 reference

Rationale for the use of aldosterone antagonists in congestive heart failure

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

54

1 reference

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

55

1 reference

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

56

1 reference

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

57

1 reference

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

59

1 reference

Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

61

1 reference

Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

62

1 reference

Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

63

1 reference

Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

64

1 reference

Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

65

1 reference

Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

66

1 reference

Vascular hypertrophy and remodeling in secondary hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

67

1 reference

Relations between cardiac and vascular structure in patients with primary and secondary hypertension.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

68

1 reference

Myocardial scintigraphic characteristics in patients with primary aldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

69

1 reference

Factors influencing outcome of surgery for primary aldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

70

1 reference

Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

72

1 reference

Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

74

1 reference

A review of the medical treatment of primary aldosteronism

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

75

1 reference

Efficacy and tolerance of spironolactone in essential hypertension.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

76

1 reference

Eplerenone--a novel selective aldosterone blocker

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

77

1 reference

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

79

1 reference

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

80

1 reference

Clinical implications of primary aldosteronism with resistant hypertension

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

81

1 reference

Renin-Independent hypermineralocorticoidism.

2 January 2024

https://api.crossref.org/works/10.1210/EN.2003-0279

82

1 reference

2 January 2024

Identifiers

DOI

10.1210/EN.2003-0279

1 reference

6 August 2017

1 reference